# Insulin Degludec Titration Using Mobile Insulin Dosing System

Study · id `cardio:ct-nct03091712` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03091712](<https://clinicaltrials.gov/study/NCT03091712>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03091712

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT03091712. Randomized; no masking; primary purpose treatment. Start 2017-05-05 (actual); primary completion 2019-08-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT03091712, source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)
- Started: 2017-05-05 (actual) (ClinicalTrials.gov record NCT03091712, source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)
- Primary completion: 2019-08-08 (actual) (ClinicalTrials.gov record NCT03091712, source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)
- Completion: 2019-09-15 (actual) (ClinicalTrials.gov record NCT03091712, source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03091712, source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03091712-2020-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Insulin Degludec Titration Using Mobile Insulin Dosing System
- Condition: Type 2 Diabetes Mellitus
- Intervention (Device): Glooko Mobile Insulin Dosing System(MIDS)
- Lead sponsor: Glooko
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 3c33e637fe4761b5e46d2426cf6284540b48463168428745a437f2acedfcfebc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
